Hyperactive Ras in developmental disorders and cancer
The DOI matches its Crossref record; 150 of the 150 references it cites were found in a registry or an index.
Abstract
Ras genes are the most common targets for somatic gain-of-function mutations in human cancer. Recently, germline mutations that affect components of the Ras-Raf-mitogen-activated and extracellular-signal regulated kinase kinase (MEK)-extracellular signal-regulated kinase (ERK) pathway were shown to cause several developmental disorders, including Noonan, Costello and cardio-facio-cutaneous syndromes. Many of these mutant alleles encode proteins with aberrant biochemical and functional properties. Here we will discuss the implications of germline mutations in the Ras-Raf-MEK-ERK pathway for understanding normal developmental processes and cancer pathogenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“NRAS or KRAS mutations are found in ;20-40% of myeloid malignancies and in 10-15% of acute lymphoblastic leukemia.4,5”
From USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism (2018) · cites this paper as [4]
In the citing paper
“Approximately 55% of colorectal cancers (CRCs) are driven by mutational activation of KRAS, BRAF, NRAS, and thus are hard-wired to oncogenic RAS/RAF/MEK/ERK pathway signaling [1–3].”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [1]
In the citing paper
“More than one-third of human tumors harbor activating RAS mutations2”
From Discovery and characterization of small molecules that target the GTPase Ral (2014) · cites this paper as [2]
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · cited 1×
“The finding that germline BRAF mutations underlie most cases of CFC syndrome is of exceptional interest to cancer biologists because, as discussed below, a V600E substitution in BRAF is one of the most common molecular lesions found in human cance”
BackgroundMassagué, J. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.753 · Cited by 7,556
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056 · cited 1×
“Akt is a kinase that promotes survival in many cell types by phosphorylating and therefore inactivating several pro-apoptotic proteins including BAD and Forkhead ( FKHR ) transcription factor”
BackgroundOncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“The overexpression of oncogenic Ras in primary cells can induce senescence or growth arrest, unless accompanied by other genetic lesions such as loss of CDKN2A (also known as p16 INK4a ), CDKN2D (also known as p19 INK4d ) or TP53 (Ref”
Backgroundras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
Marshall, C. J. (1995) · Cell · doi:10.1016/0092-8674(95)90401-8 · Cited by 3,906 · cited 1×
“For example, in PC-12 rat adrenal phaeochromocytoma cells, the transient activation of Ras through epidermal growth factor ( EGF ) signalling stimulates proliferation, whereas nerve growth factor ( NGF )-dependent sustained activation of Ras induces differentiatio”
BackgroundThe GTPase superfamily: conserved structure and molecular mechanism
Bourne, H. R., Sanders, D. A., & McCormick, F. (1991) · Nature · doi:10.1038/349117a0 · Cited by 3,392 · cited 1×
“jpg" NDATA ITEM> ]> Ras proteins are signal switch molecules that regulate cell fates by coupling receptor activation to downstream effector pathways that control diverse cellular responses including proliferation, differentiation and surviva”
BackgroundTargeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc969 · Cited by 3,256 · cited 1×
“However, KRAS and NRAS escape functional inactivation by undergoing geranylgeranylation , which, as reviewed elsewher”
BackgroundMechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
Wan, P. T. C., Garnett, M. J., Roe, S. M., Lee, S., Niculescu-Duvaz, D., Good, V. M., Project, C. G., Jones, C. M., Marshall, C. J., Springer, C. J., et al. (2004) · Cell · doi:10.1016/s0092-8674(04)00215-6 · Cited by 2,808 · cited 1×
“However, one potential confounding issue in interpreting these studies is that the levels of oncogenic V600E BRAF kinase activity relative to wild-type BRAF that were measured in this report were substantially lower than levels that others have observe”
BackgroundPreinvasive and invasive ductal pancreatic cancer and its early detection in the mouse
Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M. A., Ross, S., Conrads, T. P., Veenstra, T. D., Hitt, B. A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00309-x · Cited by 2,471 · cited 1×
“Use of tissue-specific Cre strains in the developing pancreas induced pancreatic cancer precursor lesions, and some animals developed invasive carcinomas with prolonged latency or in the presence of cooperating tumour-suppressor gene mutation”
Background
Research works printed but not linked: 1
- Roberts, A. et al. The cardio-facio-cutaneous (CFC) syndrome: a review. J. Med. Genet. (2006).
Cited by
Items 301–400 of 1,001
Targeting Ras in myeloid leukemias
Braun, B. S., & Shannon, K. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1005 · Cited by 74
Self-citationMlakar, V., Morel, E., Mlakar, S. J., Ansari, M., & Gumy‐Pause, F. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01967-x · Cited by 76
Signalling pathways underlying structural plasticity of dendritic spines
Patterson, M., & Yasuda, R. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01328.x · Cited by 90
Jun, J. E., Rubio, I., & Roose, J. P. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00239 · Cited by 93
NFAT signalling is a novel target of oncogenic BRAF in metastatic melanoma
Flockhart, R. J., Armstrong, J. L., Reynolds, N. J., & Lovat, P. E. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605277 · Cited by 79
Inhibitors of Ras–SOS Interactions
Lu, S., Jang, H., Zhang, J., & Nussinov, R. (2016) · ChemMedChem · doi:10.1002/cmdc.201500481 · Cited by 72
Staben, S. T., Feng, J. A., Lyle, K. S., Belvin, M. P., Boggs, J. W., Burch, J. D., Chua, C.-C., Cui, H., DiPasquale, A. G., Friedman, L. S., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401768t · Cited by 72
Jonckheere, N., Vasseur, R., & SEUNINGEN, I. V. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.01.002 · Cited by 82
Urosevic, J., Sauzeau, V., Soto‐Montenegro, M. L., Reig, S., Desco, M., Burkitt‐Wright, E., Cañamero, M., Mulero, F., Ortega, S., Bustelo, X. R., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016933108 · Cited by 81
Genomic Sequencing of Key Genes in Mouse Pancreatic Cancer Cells
Wang, Y., Zhang, Y., Yang, J., Ni, X., Liu, S., Li, Z., Hodges, S. E., Fisher, W. E., Brunicardi, F. C., Gibbs, R. A., et al. (2012) · Current Molecular Medicine · doi:10.2174/156652412799218868 · Cited by 78
Predicting protein targets for drug-like compounds using transcriptomics
Pabon, N. A., Xia, Y., Estabrooks, S. K., Ye, Z., Herbrand, A. K., Süß, E., Biondi, R. M., Assimon, V. A., Gestwicki, J. E., Brodsky, J. L., et al. (2018) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1006651 · Cited by 79
“HRAS and KRAS are among the most frequently mutated genes in human cancers [40, 41].”
BackgroundA new 12-gene diagnostic biomarker signature of melanoma revealed by integrated microarray analysis
Liu, W., Peng, Y., & Tobin, D. J. (2013) · PeerJ · doi:10.7717/peerj.49 · Cited by 73
Schmidt, R. L., Park, C. H., Ahmed, A. U., Gundelach, J. H., Reed, N. R., Shen, C., Knudsen, B. E., & Tang, A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4471 · Cited by 77
Oncogenic Ras abrogates MEK SUMOylation that suppresses the ERK pathway and cell transformation
Kubota, Y., O'Grady, P., Saito, H., & Takekawa, M. (2011) · Nature Cell Biology · doi:10.1038/ncb2169 · Cited by 72
“In particular, Ras proteins are activated by mutations in approximately 30p of all human cancer”
BackgroundNew Strategies for Treatment of KRAS Mutant Metastatic Colorectal Cancer
Prenen, H., Tejpar, S., & Cutsem, E. V. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2029 · Cited by 80
Mehlitz, A., Banhart, S., Mäurer, A. P., Kaushansky, A., Gordus, A. G., Zielecki, J., MacBeath, G., & Meyer, T. F. (2010) · The Journal of Cell Biology · doi:10.1083/jcb.200909095 · Cited by 71
Structure, Function, and Pathogenesis of SHP2 in Developmental Disorders and Tumorigenesis
Huang, W.-Q., Lin, Q., Zhuang, X., Cai, L.-L., Ruan, R.-S., Lu, Z.-X., & Tzeng, C.-M. (2014) · Current Cancer Drug Targets · doi:10.2174/1568009614666140717105001 · Cited by 69
Li, Z., Prakash, P., & Buck, M. (2018) · ACS Central Science · doi:10.1021/acscentsci.7b00593 · Cited by 67
Dynamics and control of the ERK signaling pathway: Sensitivity, bistability, and oscillations
Arkun, Y., & Yasemi, M. (2018) · PLoS ONE · doi:10.1371/journal.pone.0195513 · Cited by 80
Metro, G., Chiari, R., Duranti, S., Siggillino, A., Fischer, M. J., Giannarelli, D., Ludovini, V., Bennati, C., Marcomigni, L., Baldi, A., et al. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.06.005 · Cited by 75
“The kirsten rat sarcoma viral oncogene homolog (KRAS) belongs o a group of genes which encodes a family of guanosine triphoshate (GTP)-binding proteins involved in regulating pro-survival ignaling pathways downstream from EGFR [8].”
BackgroundYang, M., Haase, A. D., Huang, F.-K., Coulis, G., Rivera, K. D., Dickinson, B. C., Chang, C. J., Pappin, D., Neubert, T. A., Hannon, G. J., et al. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.07.018 · Cited by 72
KRAS as a Modulator of the Inflammatory Tumor Microenvironment: Therapeutic Implications
Pereira, F. D. S., Ferreira, A. I., Reis, C. A., Sousa, M. J., Oliveira, M. J., & Preto, A. (2022) · Cells · doi:10.3390/cells11030398 · Cited by 81
Malignant Diseases in Noonan Syndrome and Related Disorders
Hasle, H. (2009) · Hormone Research in Paediatrics · doi:10.1159/000243773 · Cited by 71
Noonan syndrome gain-of-function mutations inNRAScause zebrafish gastrulation defects
Runtuwene, V., van Eekelen, M., Overvoorde, J., Rehmann, H., Yntema, H. G., Nillesen, W. M., van Haeringen, A., van der Burgt, I., Burgering, B. M. T., & den Hertog, J. (2011) · Disease Models & Mechanisms · doi:10.1242/dmm.007112 · Cited by 82
Wu, L., Yu, K., Chen, K., Zhu, X., Yang, Z., Wang, Q., Gao, J., Wang, Y., Cao, T., Xu, H., et al. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04675-2 · Cited by 73
Voisin, L., Julien, C., Duhamel, S., Gopalbhai, K., Claveau, I., Saba-El-Leil, M. K., Rodrigue‐Gervais, I. G., Gaboury, L. A., Lamarre, D., Basik, M., et al. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-337 · Cited by 68
Flotillins in Receptor Tyrosine Kinase Signaling and Cancer
Banning, A., Kurrle, N., Meister, M., & Tikkanen, R. (2014) · Cells · doi:10.3390/cells3010129 · Cited by 73
Allostery: Allosteric Cancer Drivers and Innovative Allosteric Drugs
Nussinov, R., Zhang, M., Maloney, R., Liu, Y., Tsai, C.-J., & Jang, H. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2022.167569 · Cited by 66
Suppression of TET1-Dependent DNA Demethylation Is Essential for KRAS-Mediated Transformation
Wu, B.-K., & Brenner, C. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.10.063 · Cited by 71
Galectin-1 in Melanoma Biology and Related Neo-Angiogenesis Processes
Mathieu, V., de Lassale, E. M., Toelen, J., Mohr, T. T., Bellahcène, A., Goietsenoven, G. V., Verschuere, T., Bouzin, C., Debyser, Z., Vleeschouwer, S. D., et al. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.142 · Cited by 68
c-Myc Regulates RNA Splicing of the A-Raf Kinase and Its Activation of the ERK Pathway
Rauch, J., Moran‐Jones, K., Albrecht, V. S., Schwarzl, T., Hunter, K. D., Gires, O., & Kölch, W. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4447 · Cited by 77
Xu, J., Haigis, K. M., Firestone, A. J., McNerney, M. E., Li, Q., Davis, E., Chen, S.-C., Nakitandwe, J., Downing, J. R., Jacks, T., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0096 · Cited by 71
Self-citationOncogene-regulated release of extracellular vesicles
Kilinc, S., Paisner, R., Camarda, R., Gupta, S., Momčilović, O., Kohnz, R. A., Avşaroğlu, B., L’Étoile, N. D., Perera, R. M., Nomura, D. K., et al. (2021) · Developmental Cell · doi:10.1016/j.devcel.2021.05.014 · Cited by 75
Petanidis, S., Anestakis, D., Argyraki, M., Hadzopoulou‐Cladaras, M., & Salifoglou, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073616 · Cited by 74
Mosaic Activating RAS Mutations in Nevus Sebaceus and Nevus Sebaceus Syndrome
Sun, B. K., Saggini, A., Sarin, K. Y., Kim, J., Benjamin, L., LeBoit, P. E., & Khavari, P. A. (2012) · Journal of Investigative Dermatology · doi:10.1038/jid.2012.377 · Cited by 67
Kim, T. W., Elme, A., Kusic, Z., Park, J. O., Udrea, A. A., Kim, S. Y., Ahn, J. B., Valencia, R. V., Krishnan, S., Bilic, A., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.309 · Cited by 66
Genetic Causes of Craniosynostosis: An Update
Goos, J. A. C., & Mathijssen, I. M. J. (2018) · Molecular Syndromology · doi:10.1159/000492266 · Cited by 74
Vujic, I., Sanlorenzo, M., Posch, C., Esteve‐Puig, R., Yen, A., Kwong, A., Tsumura, A., Murphy, R. M., Rappersberger, K., & Ortiz‐Urda, S. (2014) · Oncotarget · doi:10.18632/oncotarget.2824 · Cited by 72
Vatansever, S., Erman, B., & Gumus, Z. H. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.04.003 · Cited by 69
Combined Inhibition of MEK and Plk1 Has Synergistic Antitumor Activity in NRAS Mutant Melanoma
Posch, C., Cholewa, B. D., Vujic, I., Sanlorenzo, M., Ma, J. A., Kim, S. T., Kleffel, S., Schatton, T., Rappersberger, K., Gutteridge, R. E. A., et al. (2015) · Journal of Investigative Dermatology · doi:10.1038/jid.2015.198 · Cited by 69
Liu, Y., Zhang, M., Qian, J., Bao, M., Meng, X., Zhang, S., Zhang, L., Zhao, R., Li, S., Cao, Q., et al. (2015) · DNA and Cell Biology · doi:10.1089/dna.2014.2629 · Cited by 66
Gripp, K. W., Zand, D. J., Demmer, L., Anderson, C. E., Dobyns, W. B., Zackai, E. H., Denenberg, E. H., Jenny, K., Stabley, D. L., & Sol‐Church, K. (2013) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.36098 · Cited by 73
“An increased incidence of juvenile myelomonocytic leukemia (JMML) in Noonan syndrome is related to the shared mechanism of PTPN11 missense mutations, of germline origin in Noonan syndrome and somatic in sporadic JMML [Schubbert et al., 2005, 2007].”
BackgroundPharmacokinetic and Pharmacodynamic Perspectives on the Clinical Drug Development of Panitumumab
Yang, B., Lum, P., Chen, A., Arends, R., Roskos, L. K., Smith, B. P., & Ruixo, J. J. P. (2010) · Clinical Pharmacokinetics · doi:10.2165/11535970-000000000-00000 · Cited by 73
Medina, I., Montaner, D. A., Bonifaci, N., Pujana, M. Á., Carbonell‐Caballero, J., Tárraga, J., Al‐Shahrour, F., & Dopazo, J. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp481 · Cited by 68
The Protein Tyrosine Phosphatase Receptor Delta Regulates Developmental Neurogenesis
Tomita, H., Cornejo, F., Aranda-Pino, B., Woodard, C. L., Rioseco, C. C., Neel, B. G., Alvarez, A. R., Kaplan, D. R., Miller, F. D., & Cancino, G. I. (2020) · Cell Reports · doi:10.1016/j.celrep.2019.11.033 · Cited by 67
“Genetic alterations in genes encoding components of these pathways are associated with abnormal development of the human CNS and have been implicated in human neurodevelopmental disorders (Ferguson, 2003; Schubbert et al., 2007; Levitt and Campbell, 2009; Samuels et al., 2009).”
BackgroundIdentification of mutant K-Ras-dependent phenotypes using a panel of isogenic cell lines
Vartanian, S., Bentley, C., Brauer, M. J., Li, L., Shirasawa, S., Sasazuki, T., Kim, J.-S., Haverty, P., Stawiski, E., Modrusan, Z., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.394130 · Cited by 65
El‐Mashtoly, S. F., Yosef, H. K., Petersen, D., Mavarani, L., Maghnouj, A., Hahn, S. A., Kötting, C., & Gerwert, K. B. (2015) · Analytical Chemistry · doi:10.1021/acs.analchem.5b01431 · Cited by 67
Structure‐energy‐based predictions and network modelling of RASopathy and cancer missense mutations
Kiel, C., & Serrano, L. (2014) · Molecular Systems Biology · doi:10.1002/msb.20145092 · Cited by 68
“RASopathies are a group of germline developmental disorders of the Ras-MAPK pathway, such as Noonan, cardio-facio-cutaneous (CFC), Costello and LEOPARD syndromes (Tartaglia & Gelb, 2005; Bentires-Alj et al , 2006; Schubbert et al , 2007b; Aoki et al , 2008; Tartaglia et al , 2010).”
BackgroundFrequent cases of RAS-mutated Down syndrome acute lymphoblastic leukaemia lack JAK2 mutations
Nikolaev, S. I., Garieri, M., Santoni, F. A., Falconnet, E., Ribaux, P., Guipponi, M., Murray, A., Groet, J., Giarin, E., Basso, G., et al. (2014) · Nature Communications · doi:10.1038/ncomms5654 · Cited by 64
Moran, D. M., Trusk, P. B., Pry, K., Paz, K., Sidransky, D., & Bacus, S. S. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0649 · Cited by 64
You, K. S., Yi, Y. W., Cho, J., Park, J., & Seong, Y. (2021) · Pharmaceuticals · doi:10.3390/ph14060589 · Cited by 70
RSK regulates activated BRAF signalling to mTORC1 and promotes melanoma growth
Roméo, Y., Moreau, J., Zindy, P.-J., Saba-El-Leil, M. K., Lavoie, G., Dandachi, F., Baptissart, M., Borden, K. L. B., Meloche, S., & Roux, P. P. (2012) · Oncogene · doi:10.1038/onc.2012.312 · Cited by 72
Kwon, M. J., Lee, S. E., Kang, S. Y., & Choi, Y. (2011) · Pathology - Research and Practice · doi:10.1016/j.prp.2011.10.002 · Cited by 65
Juanpere-Rodero, N., Agell, L., Lorenzo, M., de Muga, S., López-Vilaró, L., Murillo, R., Mojal, S., Serrano, S., Lorente, J. A., Lloreta, J., et al. (2012) · Human Pathology · doi:10.1016/j.humpath.2011.10.026 · Cited by 66
Murphy, M. P., & Stordal, B. (2011) · Drug Resistance Updates · doi:10.1016/j.drup.2011.02.004 · Cited by 71
Dynamics of Membrane-Bound G12V-KRAS from Simulations and Single-Molecule FRET in Native Nanodiscs
Prakash, P., Litwin, D. B., Hong, L., Sarkar‐Banerjee, S., Dolino, D. M., Zhou, Y., Hancock, J. F., Jayaraman, V., & Gorfe, A. A. (2018) · Biophysical Journal · doi:10.1016/j.bpj.2018.12.011 · Cited by 62
Spurlock, G., Knight, S. J. L., Thomas, N. S. T., Kiehl, T., Guha, A., & Upadhyaya, M. (2010) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-010-0846-3 · Cited by 61
Barceló, C., Etchin, J., Mansour, M. R., Sanda, T., Morell, M., Lobo, V. J. S.-A., Real, F. X., Capellá, G., Estanyol, J. M., Jaumot, M., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.06.041 · Cited by 68
Cutaneous skeletal hypophosphatemia syndrome (CSHS) is a multilineage somatic mosaic RASopathy
Lim, Y. H., Ovejero, D., Derrick, K. M., Collins, M. T., & Choate, K. A. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.11.012 · Cited by 63
Hodges, T. R., Abbott, J. R., Little, A. J., Sarkar, D., Salovich, J. M., Howes, J. E., Akan, D. T., Sai, J., Arnold, A. L., Browning, C. F., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01108 · Cited by 62
Colorectal cancer-related mutant KRAS alleles function as positive regulators of autophagy
Alves, S., Castro, L., Fernandes, M. S., Francisco, R., Castro, P. J. T. D., Priault, M., Chaves, S. R., Moyer, M. P., Oliveíra, C., Seruca, R., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5021 · Cited by 74
Ashton‐Beaucage, D., Udell, C. M., Gendron, P., Sahmi, M., Lefrançois, M., Baril, C., Guenier, A.-S., Duchaine, J., Lamarre, D., Lemieux, S., et al. (2014) · PLoS Biology · doi:10.1371/journal.pbio.1001809 · Cited by 64
Mita, H., Toyota, M., Aoki, F., Akashi, H., Maruyama, R., Sasaki, Y., Suzuki, H., Idogawa, M., Kashima, L., Yanagihara, K., et al. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-198 · Cited by 65
Phosphorylation at Ser-181 of Oncogenic KRAS Is Required for Tumor Growth
Barceló, C., Paco, N., Morell, M., Alvarez-Moya, B., Bota‐Rabassedas, N., Jaumot, M., Vilardell, F., Capellá, G., & Agell, N. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1750 · Cited by 62
Acuña‐Hidalgo, R., Deriziotis, P., Steehouwer, M., Gilissen, C., Graham, S. A., van Dam, S., Hoover-Fong, J. E., Telegrafi, A. B., Destrèe, A., Śmigiel, R. S., et al. (2017) · PLoS Genetics · doi:10.1371/journal.pgen.1006683 · Cited by 65
The Molecular Genetics of Myeloproliferative Neoplasms
Marneth, A. E., & Mullally, A. (2019) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a034876 · Cited by 68
“Heterozygous missense substitutions at NRAS/ KRAS codons 12, 13, and 61 are most common and favor the GTP-bound state of RAS because of reduced intrinsic GTP hydrolysis and resistance to GAPs (Schubbert et al. 2007).”
BackgroundMolecular markers for colon diagnosis, prognosis and targeted therapy
Herzig, D. O., & Tsikitis, V. L. (2014) · Journal of Surgical Oncology · doi:10.1002/jso.23806 · Cited by 70
Slape, C. I., Liu, L. Y., Beachy, S. H., & Aplan, P. D. (2008) · Blood · doi:10.1182/blood-2008-01-135186 · Cited by 61
Zhang, J., Zhang, J., Xu, S., Zhang, X., Wang, P., Wu, H., Xia, B., Zhang, G., Lei, B., Wan, L., et al. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000487162 · Cited by 61
Hecht, J. R., Douillard, J., Schwartzberg, L. S., Grothey, A., Kopetz, S., Rong, A., Oliner, K. S., & Sidhu, R. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.05.008 · Cited by 67
RhoA as a Mediator of Clinically Relevant Androgen Action in Prostate Cancer Cells
Schmidt, L. J., Duncan, K., Yadav, N., Regan, K. M., Verone, A. R., Lohse, C. M., POP, E. A., Attwood, K. M., Wilding, G. E., Mohler, J. L., et al. (2012) · Molecular Endocrinology · doi:10.1210/me.2011-1130 · Cited by 75
KRAS induces lung tumorigenesis through microRNAs modulation
Shi, L., Middleton, J. D., Jeon, Y.-J., Magee, P., Veneziano, D., Laganà, A., Leong, H. S., Sahoo, S., Fassan, M., Booton, R., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0243-9 · Cited by 60
Enhancement of Cancer-Specific Protoporphyrin IX Fluorescence by Targeting Oncogenic Ras/MEK Pathway
Yoshioka, E., Chelakkot, V. S., Licursi, M., Rutihinda, S. G., Som, J., Derwish, L., King, J. J., Pongnopparat, T., Mearow, K. M., Larijani, M., et al. (2018) · Theranostics · doi:10.7150/thno.22641 · Cited by 66
Sanchez‐Ortiz, E., Cho, W., Nazarenko, I., Mo, W., Chen, J., & Parada, L. F. (2014) · Genes & Development · doi:10.1101/gad.246603.114 · Cited by 61
Therapeutic Potential of Targeting PAK Signaling
Senapedis, W. T., Crochiere, M. L., Baloglu, E., & Landesman, Y. (2015) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520615666150617111414 · Cited by 73
Usha, T., Middha, S. K., Kumar, A., Mahesh, K., Manoj, D. A., Syed, F., Peyush, G., Kumar, H. P., & Pande, V. (2014) · Journal of Biomedical Research · doi:10.7555/jbr.28.20130110 · Cited by 59
Hong, S., Jin, D., Shin, J.-S., Moon, J.-H., Na, Y.-S., Jung, K., Kim, S.-M., Kim, J. C., Kim, K., Hong, Y. S., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.319822 · Cited by 64
Preto, A., Figueiredo, J., Velho, S., Ribeiro, A., Soares, P., Oliveíra, C., & Seruca, R. (2007) · The Journal of Pathology · doi:10.1002/path.2295 · Cited by 60
Bakker, M. K., Pajkrt, E., Mathijssen, I. B., & Bilardo, C. M. (2011) · Prenatal Diagnosis · doi:10.1002/pd.2782 · Cited by 59
Modelling oncogenic Ras/Raf signalling in the mouse
Karreth, F. A., & Tuveson, D. A. (2009) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2008.12.006 · Cited by 69
Targeting the RAS/MAPK pathway withmiR-181ain acute myeloid leukemia
Huang, X., Schwind, S., Santhanam, R., Eisfeld, A., Chiang, C., Lankenau, M. A., Yu, B., Hoellerbauer, P., Jin, Y., Tarighat, S. S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11150 · Cited by 59
Lee, S. A., Ladu, S., Evert, M., Dombrowski, F., Murtas, V. D., Chen, X., & Calvisi, D. F. (2010) · Hepatology · doi:10.1002/hep.23681 · Cited by 65
Chen, T.-L., Chang, C., Lin, Y., Ueng, Y., & Chen, R. (2009) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2009.06.013 · Cited by 59
The roles of FOXM1 in pancreatic stem cells and carcinogenesis
Quan, M., Wang, P., Cui, J., Gao, Y., & Xie, K. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-159 · Cited by 62
Cazzanelli, G., Pereira, F. D. S., Alves, S., Francisco, R., Azevedo, L., Carvalho, P. D., Almeida, A. F., Côrte‐Real, M., Oliveira, M. J., Lucas, C., et al. (2018) · Cells · doi:10.3390/cells7020014 · Cited by 62
Wang, Z., Liu, Y., Takahashi, M., Hook, K. V., Kampa-Schittenhelm, K. M., Sheppard, B. C., Sears, R. C., Stork, P. A., & Lopez, C. D. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1201514110 · Cited by 58
Polysialylated NCAM Represses E-Cadherin-Mediated Cell-Cell Adhesion in Pancreatic Tumor Cells
Schreiber, S. C., Giehl, K., Kastilan, C., Hasel, C., Mühlenhoff, M., Adler, G., Wedlich, D., & Menke, A. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.02.023 · Cited by 57
Damiano, L., Stefano, P. D., Leal, M. D. P. C., Barba, M., Mainiero, F., Cabodi, S., Tordella, L., Sapino, A., Castellano, I., Canel, M., et al. (2010) · Oncogene · doi:10.1038/onc.2010.128 · Cited by 62
Selective requirement for Mediator MED23 in Ras-active lung cancer
Xu, Y., Zhao, M. L., Xia, M. H., Liu, Y., Yan, J., Ji, H., & Wang, G. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1204311109 · Cited by 62
Won, J. H., Zhang, Y., Ji, B., Logsdon, C. D., & Yule, D. I. (2010) · Molecular Biology of the Cell · doi:10.1091/mbc.e10-10-0807 · Cited by 65
Phan, V. T., Ding, V. W., Li, F., Chalkley, R. J., Burlingame, A. L., & McCormick, F. P. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.01450-08 · Cited by 58
Epigenetic inactivation of RASSF2 in oral squamous cell carcinoma
Imai, T., Toyota, M., Suzuki, H., Akino, K., Ogi, K., Sogabe, Y., Kashima, L., Maruyama, R., Nojima, M., Mita, H., et al. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00769.x · Cited by 57
Fujita-Sato, S., Galeas, J., Truitt, M., Pitt, C., Urisman, A., Bandyopadhyay, S., Ruggero, D., & McCormick, F. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-1623 · Cited by 55
Role of miRNALet-7and Its Major Targets in Prostate Cancer
Wagner, S., Ngezahayo, A., Escobar, H. M., & Nolte, I. J. A. (2014) · BioMed Research International · doi:10.1155/2014/376326 · Cited by 67
Pasmant, É., Gilbert‐Dussardier, B., Petit, A., de Laval, B., Luscan, A., Gruber, A., Lapillonne, H., Deswarte, C., Goussard, P., Laurendeau, I., et al. (2014) · Oncogene · doi:10.1038/onc.2013.587 · Cited by 64
Endometrial Carcinoma: Specific Targeted Pathways
Eritja, N., Yeramian, A., Chen, B., Llobet‐Navàs, D., Ortega, E., Colás, E., Abal, M., Dolcet, X., Reventós, J., & Matías‐Guiu, X. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-43139-0_6 · Cited by 64
Zeiser, R., Andrlová, H., & Meiß, F. (2018) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-91442-8_7 · Cited by 60
Rit subfamily small GTPases: Regulators in neuronal differentiation and survival
Shi, G., Cai, W., & Andres, D. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2013.06.002 · Cited by 61
NORE1A is a Ras senescence effector that controls the apoptotic/senescent balance of p53 via HIPK2
Donninger, H., Calvisi, D. F., Barnoud, T., Clark, J., Schmidt, M., Vos, M. D., & Clark, G. J. (2015) · The Journal of Cell Biology · doi:10.1083/jcb.201408087 · Cited by 60
Recent advances in personalized colorectal cancer research
Kraus, S. R., Nabiochtchikov, I., Shapira, S., & Arber, N. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.01.025 · Cited by 56
“constitutive activation of downstream signaling pathways and confer resistance to inhibition of cell surface receptor tyrosine kinases, particularly EGFR [7], resulting in 26–41% response rates for cetuximab and 11–17% for panitumumab, suggesting the involvement of additional activating mutations in the resistance to…”
Background
Metadata
- Authors
- Schubbert, S., Shannon, K., & Bollag, G.
- Affiliations
- University of California, San Francisco (US)
- Plexxikon (United States) (US)
- Corresponding author
- Bollag, Gideon
- Venue
- Nature Reviews Cancer
- Published
- 2007-04
- Volume
- 7
- Issue
- 4
- Pages
- 295-308
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2088293068
- Cited by
- 1,583
- References
- 150
- Citations by year
- 2026: 24 · 2025: 30 · 2024: 47 · 2023: 61 · 2022: 46 · 2021: 68 · 2020: 59 · 2019: 64 · 2018: 75 · 2017: 84 · 2016: 102 · 2015: 101 · 2014: 150 · 2013: 141 · 2012: 116
- FWCI
- 7.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Leukemia and Lymphoma Society
- National Cancer Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- Ras signaling, germline mutations, Noonan syndrome, Costello syndrome, cardiofaciocutaneous syndrome, MEK/ERK signaling, Raf, developmental disorders, carcinogenesis, gain-of-function mutations, MAPK signaling
- MeSH terms
- Developmental Disabilities, Child, Preschool, Gene Expression Regulation, Humans, Models, Molecular, Neoplasms, Genes, ras, Signal Transduction, Protein Tyrosine Phosphatases, Germ-Line Mutation, Proto-Oncogene Proteins c-raf, Mitogen-Activated Protein Kinases, Mitogen-Activated Protein Kinase Kinases, MAP Kinase Signaling System, Intracellular Signaling Peptides and Proteins, Extracellular Signal-Regulated MAP Kinases, Proto-Oncogene Proteins B-raf, Protein Tyrosine Phosphatase, Non-Receptor Type 11
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.